SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MERIGHI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.903
AS - Asia 11.363
EU - Europa 6.496
SA - Sud America 1.749
AF - Africa 265
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 8
Totale 39.806
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.475
SG - Singapore 4.174
CN - Cina 2.956
DE - Germania 1.349
BR - Brasile 1.331
VN - Vietnam 1.272
IT - Italia 1.063
UA - Ucraina 1.014
HK - Hong Kong 937
TR - Turchia 757
GB - Regno Unito 645
FI - Finlandia 512
FR - Francia 445
SE - Svezia 377
RU - Federazione Russa 351
JP - Giappone 281
PL - Polonia 270
IN - India 236
CA - Canada 213
MX - Messico 164
AR - Argentina 152
BD - Bangladesh 149
NL - Olanda 118
ID - Indonesia 109
IQ - Iraq 98
ZA - Sudafrica 93
ES - Italia 79
CO - Colombia 56
EC - Ecuador 56
PK - Pakistan 56
LT - Lituania 51
BE - Belgio 49
VE - Venezuela 48
MA - Marocco 43
CL - Cile 38
MY - Malesia 38
SA - Arabia Saudita 37
UZ - Uzbekistan 34
AE - Emirati Arabi Uniti 32
PH - Filippine 25
AT - Austria 24
PY - Paraguay 24
TN - Tunisia 24
KE - Kenya 23
CZ - Repubblica Ceca 22
EG - Egitto 22
IL - Israele 19
AU - Australia 18
DZ - Algeria 18
NP - Nepal 18
JO - Giordania 17
IE - Irlanda 15
KR - Corea 15
PE - Perù 14
UY - Uruguay 14
BO - Bolivia 12
AL - Albania 11
PT - Portogallo 10
TW - Taiwan 10
CH - Svizzera 9
OM - Oman 9
RO - Romania 9
GR - Grecia 8
IR - Iran 8
TH - Thailandia 8
AZ - Azerbaigian 7
ET - Etiopia 7
HN - Honduras 7
HU - Ungheria 7
KG - Kirghizistan 7
NI - Nicaragua 7
RS - Serbia 7
SN - Senegal 7
BG - Bulgaria 6
CR - Costa Rica 6
EU - Europa 6
JM - Giamaica 6
AO - Angola 5
BA - Bosnia-Erzegovina 5
GT - Guatemala 5
HR - Croazia 5
KZ - Kazakistan 5
LB - Libano 5
LV - Lettonia 5
NG - Nigeria 5
NO - Norvegia 5
PA - Panama 5
PS - Palestinian Territory 5
SV - El Salvador 5
AM - Armenia 4
BH - Bahrain 4
BY - Bielorussia 4
GE - Georgia 4
MN - Mongolia 4
QA - Qatar 4
SK - Slovacchia (Repubblica Slovacca) 4
SY - Repubblica araba siriana 4
CG - Congo 3
CI - Costa d'Avorio 3
CY - Cipro 3
Totale 39.745
Salva come PNG Salva come JPEG
Città #
Singapore 2.736
Ashburn 2.168
Woodbridge 1.755
Fairfield 1.554
San Jose 1.311
Jacksonville 1.095
Chandler 1.077
Houston 1.057
Hong Kong 917
Beijing 915
Ann Arbor 878
Santa Clara 850
Seattle 661
Wilmington 642
Cambridge 533
Ho Chi Minh City 440
Dallas 407
Izmir 366
Los Angeles 363
Nanjing 336
Hanoi 311
Ferrara 308
Tokyo 266
Princeton 255
Warsaw 243
New York 222
Munich 220
Lauterbourg 219
Helsinki 217
Milan 213
Boardman 203
Shanghai 149
Council Bluffs 146
São Paulo 145
Dearborn 126
San Diego 115
Shenyang 111
Orem 109
Nanchang 105
London 98
Addison 90
Hefei 90
Tianjin 88
Mexico City 87
Falkenstein 85
Montreal 83
Bremen 82
Turku 80
Buffalo 79
Frankfurt am Main 76
Jakarta 73
Changsha 66
Hebei 64
Chicago 63
Da Nang 62
Chennai 59
Brooklyn 58
Toronto 56
Haiphong 54
Bologna 51
Jinan 49
Johannesburg 48
San Francisco 48
Brussels 47
Manchester 47
Jiaxing 46
Atlanta 44
Denver 44
Moscow 43
San Mateo 43
Stockholm 43
Poplar 42
Amsterdam 40
Boston 40
Baghdad 39
Falls Church 39
Rio de Janeiro 39
The Dalles 39
Phoenix 37
Kunming 36
Zhengzhou 36
Mountain View 35
Norwalk 33
Mumbai 32
Guangzhou 31
Tashkent 31
Rome 29
Biên Hòa 27
Auburn Hills 26
Ningbo 26
Ankara 25
Brasília 25
Philadelphia 25
Redwood City 25
Columbus 24
Belo Horizonte 23
Hải Dương 23
Charlotte 22
Medellín 22
Dhaka 21
Totale 26.682
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Adenosine Receptors: The State of the Art 381
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 328
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 310
A glance at adenosine receptors: Novel target for antitumor therapy 307
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 284
The A3 adenosine receptor: history and perspectives 276
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 272
A(2B) adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway 263
Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields 258
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 258
Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? 255
A1 and A3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes 253
Adenosine receptors and human melanoma 253
Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter 244
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 244
Antioxidant and antiinflammatory effects of epilobium parviflorum, melilotus officinalis and cardiospermum halicacabum plant extracts in macrophage and microglial cells 242
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 240
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 239
Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields 234
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 232
Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells 232
Multiple sclerosis lymphocytes upregulate A(2A) adenosine receptors that are antiinflammatory when stimulated 230
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 227
The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia 226
Adenosine receptors and cancer 222
Adenosine receptor targeting in health and disease 222
HIF-1 neuroprotection through erythropoietin increase in hypoxia: a role for A1 adenosine receptors 220
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study 218
van't Hoff Based Thermodynamics 218
The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells 216
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells 214
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats 213
[3H]-MRE 2029-F20, a novel selective antagonist radioligand, for the pharmacological and biochemical characterization of A2B receptors. 211
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 210
Agonists and antagonists: Molecular mechanisms and therapeutic applications 210
A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells 209
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 208
Synthesis and pharmacology of 6-substituted benztropines: Discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter 208
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 207
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors 207
Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells 206
Pathological overproduction: the bad side of adenosine 206
[3H]MRE2029F20 a new selective antagonist radioligand for the human A2B adenosine receptors. 204
Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine receptors. 202
Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation 202
Adenosine and lymphocyte regulation 202
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 201
Adenosine receptors in health and disease 201
Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. 200
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: A pharmacological and biochemical study. 200
Receptor binding thermodynamics as a tool for linking drug efficacy and affinity 199
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 199
Targeting A3 and A2A adenosine receptors in the fight against cancer 198
[3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 197
Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields 196
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 196
Binding thermodynamic characterization of human P2X1 and P2X3 purinergic receptors 193
Pharmacological characterization of adenosine receptors in bovine chondrocytes. 193
Thermodynamic analysis in drug-receptor binding: the A3 adenosine receptor 193
Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB2receptor antagonists/inverse agonists 193
Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour 192
THERMODYNAMICS OF A2B ADENOSINE RECEPTOR BINDING DISCRIMINATES AGONISTIC FROM ANTAGONISTIC BEHAVIOUR 192
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. 191
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemiotherapic drugs: taxol and vindesine. 190
A3 adenosine receptors in human neutrophils and promyelocitic HL60 cells: a pharmacological and biochemical study. 189
Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors 189
Biochemical and pharmacological role of A1adenosine receptors and their modulation as novel therapeutic strategy 189
[3H]MRE3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 188
A(2A) adenosine receptors in human peripheral blood cells 187
Pulsed electromagnetic field and relief of hypoxia-induced neuronal cell death: The signaling pathway 187
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 186
New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A(3) adenosine receptor antagonists 185
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1α, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells 185
Adenosine in a human model of Hypoxic foam cells 185
New potent and selective human adenosine A3 receptor antagonists. 184
MODULATION OF MMP-9 IN U87MG GLIOBLASTOMA CELLS BY A3 ADENOSINE RECEPTORS 182
Effect of low frequency electromagnetic fields on A2A and A3 adenosine receptors in human neutrophils 179
Adenosine modulates HIF-1, VEGF, IL-8 and foam cells formation in a human model of hypoxic foam cells 179
L'ipossia inibisce l'apoptosi indotta da paclitaxel mediante fosforilazione di BAD dipendente dall'adenosina nelle cellule di glioblastoma. 178
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. 178
Hydrogen sulfide modulates the release of nitric oxide and VEGF in human keratinocytes. 178
Binding and functional parameters of A2A adenosine receptors in essential hypertensive patients before and after pharmacological treatment 177
Design, synthesis, and biological evaluation of C-9- and C-2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines as new A(2A) and A(3) adenosine receptors antagonists 176
[3H]-MRE 2029-F20, A Novel Selective Antagonist Radiolig and, for the Pharmacological and Biochemical Characterization of A2B Receptors. 176
Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. 176
Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells 176
MODULATION OF THE AKT/RAS/RAF/MEK/ERK PATHWAY BY A3 ADENOSINE RECEPTOR 176
New potent and selective human adenosine A3 receptor antagonists 176
A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease 176
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 174
Adenosine modulates HIF-1α, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells 174
The A3 adenosine receptor: An enigmatic player in cell biology 173
Recettori dell'adenosina in tessuti tumorali e in linee cellulari di colon:"focus" sul recettore A3. 173
Expression, pharmacological profile and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells by using a novel selective antagonist radioligand, [3H]MRE2029F20. 173
Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors 172
Effect of low frequency electromagnetic fields on A2A and A3 adenosine receptors in human neutrophils 172
Adenosine A2A receptors in human circulating blood elements 171
Cannabinoid CB2 receptor modulates microglial cell activation: role of ERK-1/2 Kinase signaling. 171
Adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes 170
A3 ADENOSINE RECEPTORS MODULATE HYPOXIA-INDUCIBLE FACTOR-1ALPHA EXPRESSION IN HUMAN CANCER CELLS 169
Totale 20.876
Salva come PNG Salva come JPEG
Categoria #
all - tutte 163.864
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.600
Totale 170.464
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021526 0 0 0 0 0 0 0 0 0 0 369 157
2021/20222.157 45 228 152 75 84 97 81 104 76 183 322 710
2022/20232.535 245 223 91 337 424 325 140 203 291 24 143 89
2023/20241.272 113 168 44 27 131 139 53 93 32 54 65 353
2024/20255.622 128 192 419 289 701 522 246 315 741 638 786 645
2025/202615.084 1.635 571 1.351 1.978 2.329 1.110 1.903 797 1.611 1.788 11 0
Totale 40.139